@entity1243 and @entity1254 as predictors of disease activity in XXXX .

@entity1 @entity28 @entity1243 @entity1254 @entity230 @entity309
OBJECTIVES: To assess whether baseline levels of @entity1243 and @entity1254 predict disease activity or response to treatment in @entity1 with @entity309 at 6 months, 1 and 2 years of follow-up. METHODS: A consecutive cohort of @entity1 , classified according to the 2010 ACR/EULAR @entity309 criteria, was evaluated at baseline, 6 months, 1 and 2 years. All were treated with @entity230 and/or DMARDs. None received biologics. Blood was taken at a baseline to determine plasma anti-CCP, @entity1243 and @entity1254 . The relationship between @entity1243 , @entity1254 , DAS28 and changes in DAS28 was assessed by multivariable linear and logistic regression from baseline to follow-up. RESULTS: 127 @entity1 completed 6 months, 91 one year and 52 two years of follow-up. All were female, mean age 45 years (18-70), time since onset of disease 7.5 years (0-36). A U-shaped relationship between DAS28 and @entity1243 baseline levels was seen. Adjusting for different factors, @entity1243 levels at baseline predicted higher DAS28 at 6 months and, in @entity1 who were not overweight or @entity28 , predicted disease activity at 6 months, 1 and 2 years. In @entity1 who were not overweight or @entity28 , baseline @entity1243 was able to predict response to treatment at 6 and 12 months. CONCLUSIONS: In the short term, baseline @entity1243 levels predict disease activity in all @entity309 @entity1 and response to treatment in @entity309 @entity1 with normal weight.
